LGND
LGND
US53220K5048
Ligand Pharmaceuticals Incorpor
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
6.02B EUR
6.3B EUR
4B EUR
3.74B EUR
Enterprise Value
5.65B EUR
6.42B EUR
4.34B EUR
4.02B EUR
Valuation Multiples
Trailing P/E
31.8x
31.93x
26.04x
22.4x
Forward P/E
25.26x
--
--
--
Price to Sales
20.71x
21.67x
14.57x
16.78x
Price to Book
6.21x
6.51x
4.01x
3.68x
EV/Revenue
19.46x
22.1x
15.8x
18.03x
EV/EBITDA
42.51x
40.19x
28.11x
32.6x
Price to FCF (P/FCF)
43.05x
52.58x
35.08x
57.06x
EV/FCF
40.46x
53.62x
38.04x
61.28x
FCF Yield
2.32%
1.9%
2.85%
1.75%
ende